Multiomic research, facilitated by next-generation sequencing (NGS), has enabled researchers to understand molecular mechanisms from different sample types and analytes. Integrating genomic data with RNA expression and other ′omics data can lead to a comprehensive and deep understanding of biological processes. 

In this webinar, we introduce the QIAseq Multimodal DNA/RNA Library Kit, a multiomic solution for DNA and RNA library preparation from a single sample. The kit offers high flexibility, as it is compatible with most starting materials and can easily be adapted to your preferred sequencing breadth – from WGS/WTS to targeted sequencing.  Moreover, the integration of unique molecular indices (UMIs), rRNA removal and hybrid capture technologies makes the workflow well-suited for a range of applications that warrant examining DNA, RNA or both modalities from a single sample.

As the demand for personalized cancer treatment grows, clinical diagnostic labs are facing unprecedented pressure to scale-up, increase test throughput, reduce turnaround times, and deliver comprehensive, oncologist-ready reports that match patients to the most appropriate therapies and clinical trials, in a time-efficient manner.

In this webinar, learn how QIAGEN Clinical Insight (QCI) Interpret for Oncology, the world’s leading variant interpretation and reporting software, can help your lab accelerate your clinical reporting workflow for high-throughput precision oncology NGS testing. The webinar will demonstrate the capabilities and features of QCI Interpret for Oncology through an example workflow for comprehensive genomic profiling. Key highlights include the software’s capability to expedite variant interpretation, dynamically compute pathogenicity and actionability based on the ACMG and AMP/ASCO/CAP guidelines for every variant in over 30,000 cancer types and subtypes with full transparency. Additionally learn how to leverage over 500,000 pre-formulated, oncologist-reviewed variant interpretation summaries to build customizable, oncologist-ready reports with up-to-date gene, variant, diagnostic, prognostic and therapeutic information.

Topics covered in this webinar: 

• QCI Interpret for Oncology’s new performance and scalability enhancements, including bulk variant assessment, flagging of co-occurring variants, and a somatic reporting policy that allows users to set pathogenicity in a phenotype-agnostic manner.
• Learn how the panel- and sequencer-agnostic software can facilitate true scalability by rendering efficient test and process management capabilities, quick identification and comparison of tests from a patient for follow-up.
• How the software’s underlying knowledge base combines the unmatched accuracy and consistency of QIAGEN’s proprietary expert (MD/PhD) curation with the superior efficiency of machine curation (AI-powered) to identify all the literature, treatments, and clinical trials relevant to a patient’s tumor type with just one-click.

As the demand for personalized cancer treatment grows, clinical diagnostic labs are facing unprecedented pressure to scale-up, increase test throughput, reduce turnaround times, and deliver comprehensive, oncologist-ready reports that match patients to the most appropriate therapies and clinical trials, in a time-efficient manner.

In this webinar, learn how QIAGEN Clinical Insight (QCI) Interpret for Oncology, the world’s leading variant interpretation and reporting software, can help your lab accelerate your clinical reporting workflow for high-throughput precision oncology NGS testing. The webinar will demonstrate the capabilities and features of QCI Interpret for Oncology through an example workflow for comprehensive genomic profiling. Key highlights include the software’s capability to expedite variant interpretation, dynamically compute pathogenicity and actionability based on the ACMG and AMP/ASCO/CAP guidelines for every variant in over 30,000 cancer types and subtypes with full transparency. Additionally learn how to leverage over 500,000 pre-formulated, oncologist-reviewed variant interpretation summaries to build customizable, oncologist-ready reports with up-to-date gene, variant, diagnostic, prognostic and therapeutic information.

Topics covered in this webinar: 

• QCI Interpret for Oncology’s new performance and scalability enhancements, including bulk variant assessment, flagging of co-occurring variants, and a somatic reporting policy that allows users to set pathogenicity in a phenotype-agnostic manner.
• Learn how the panel- and sequencer-agnostic software can facilitate true scalability by rendering efficient test and process management capabilities, quick identification and comparison of tests from a patient for follow-up.
• How the software’s underlying knowledge base combines the unmatched accuracy and consistency of QIAGEN’s proprietary expert (MD/PhD) curation with the superior efficiency of machine curation (AI-powered) to identify all the literature, treatments, and clinical trials relevant to a patient’s tumor type with just one-click.

As the demand for personalized cancer treatment grows, clinical diagnostic labs are facing unprecedented pressure to scale-up, increase test throughput, reduce turnaround times, and deliver comprehensive, oncologist-ready reports that match patients to the most appropriate therapies and clinical trials, in a time-efficient manner.

In this webinar, learn how QIAGEN Clinical Insight (QCI) Interpret for Oncology, the world’s leading variant interpretation and reporting software, can help your lab accelerate your clinical reporting workflow for high-throughput precision oncology NGS testing. The webinar will demonstrate the capabilities and features of QCI Interpret for Oncology through an example workflow for comprehensive genomic profiling. Key highlights include the software’s capability to expedite variant interpretation, dynamically compute pathogenicity and actionability based on the ACMG and AMP/ASCO/CAP guidelines for every variant in over 30,000 cancer types and subtypes with full transparency. Additionally learn how to leverage over 500,000 pre-formulated, oncologist-reviewed variant interpretation summaries to build customizable, oncologist-ready reports with up-to-date gene, variant, diagnostic, prognostic and therapeutic information.

Topics covered in this webinar: 

• QCI Interpret for Oncology’s new performance and scalability enhancements, including bulk variant assessment, flagging of co-occurring variants, and a somatic reporting policy that allows users to set pathogenicity in a phenotype-agnostic manner.
• Learn how the panel- and sequencer-agnostic software can facilitate true scalability by rendering efficient test and process management capabilities, quick identification and comparison of tests from a patient for follow-up.
• How the software’s underlying knowledge base combines the unmatched accuracy and consistency of QIAGEN’s proprietary expert (MD/PhD) curation with the superior efficiency of machine curation (AI-powered) to identify all the literature, treatments, and clinical trials relevant to a patient’s tumor type with just one-click.

As the demand for personalized cancer treatment grows, clinical diagnostic labs are facing unprecedented pressure to scale-up, increase test throughput, reduce turnaround times, and deliver comprehensive, oncologist-ready reports that match patients to the most appropriate therapies and clinical trials, in a time-efficient manner.

In this webinar, learn how QIAGEN Clinical Insight (QCI) Interpret for Oncology, the world’s leading variant interpretation and reporting software, can help your lab accelerate your clinical reporting workflow for high-throughput precision oncology NGS testing. The webinar will demonstrate the capabilities and features of QCI Interpret for Oncology through an example workflow for comprehensive genomic profiling. Key highlights include the software’s capability to expedite variant interpretation, dynamically compute pathogenicity and actionability based on the ACMG and AMP/ASCO/CAP guidelines for every variant in over 30,000 cancer types and subtypes with full transparency. Additionally learn how to leverage over 500,000 pre-formulated, oncologist-reviewed variant interpretation summaries to build customizable, oncologist-ready reports with up-to-date gene, variant, diagnostic, prognostic and therapeutic information.

Topics covered in this webinar: 

• QCI Interpret for Oncology’s new performance and scalability enhancements, including bulk variant assessment, flagging of co-occurring variants, and a somatic reporting policy that allows users to set pathogenicity in a phenotype-agnostic manner.
• Learn how the panel- and sequencer-agnostic software can facilitate true scalability by rendering efficient test and process management capabilities, quick identification and comparison of tests from a patient for follow-up.
• How the software’s underlying knowledge base combines the unmatched accuracy and consistency of QIAGEN’s proprietary expert (MD/PhD) curation with the superior efficiency of machine curation (AI-powered) to identify all the literature, treatments, and clinical trials relevant to a patient’s tumor type with just one-click.

ForenSeq Kintelligence is an integrated solution for Forensic Investigative Genetic Genealogy (FIGG). With this kit, you can prepare libraries and sequence and analyze them in a single, streamlined workflow for efficient assessment of forensically relevant SNPs. This webinar will cover the internal validation of ForenSeq Kintelligence Kit at Signature Science’s Center for Advanced Genomics. 

• Optimized methods were incorporated to improve performance, particularly with low-input samples. 
• The validation testing following SWGDAM standards demonstrated sensitivity down to 50 pg of DNA, high precision and accuracy, the ability to detect mixtures, negligible contamination and high performance with nonprobative samples.
• The validated protocol is being applied to current, in-house casework on challenging samples resulting in high call rates. 

Michelle Peck from Signature Science, LLC will also discuss the next steps toward the analysis of mixture samples. This webinar is brought to you by QIAGEN Human Identification and Forensics.

ForenSeq Kintelligence is an integrated solution for Forensic Investigative Genetic Genealogy (FIGG). With this kit, you can prepare libraries and sequence and analyze them in a single, streamlined workflow for efficient assessment of forensically relevant SNPs. This webinar will cover the internal validation of ForenSeq Kintelligence Kit at Signature Science’s Center for Advanced Genomics. 

• Optimized methods were incorporated to improve performance, particularly with low-input samples. 
• The validation testing following SWGDAM standards demonstrated sensitivity down to 50 pg of DNA, high precision and accuracy, the ability to detect mixtures, negligible contamination and high performance with nonprobative samples.
• The validated protocol is being applied to current, in-house casework on challenging samples resulting in high call rates. 

Michelle Peck from Signature Science, LLC will also discuss the next steps toward the analysis of mixture samples. This webinar is brought to you by QIAGEN Human Identification and Forensics.

Developing a new product is exhilarating. But whether it’s enzyme, oligo, buffer, instrument or application, the path to innovation can be fraught with obstacles. And whether it be customization, R&D, compliance, regulation, kitting or supply chain security the right partner can help to smooth the bumps and straighten the curves.

This webinar examines the challenges assay manufacturers face when searching for a partner for bulk biotech supply. We’ll review key factors for success – development capabilities, customization, confidentiality, quality, scaling and consistency, as well as give an overview of our expansive enzyme portfolio. In this webinar, learn how you can ensure your criteria for formulation, quantities, compliance and timelines are met – an entire strategic plan from discovery to delivery.

The QIAGEN Strategic Partnerships program brings over 40 years of scientific, operational, customization and OEM expertise to the table, allowing businesses of any size to accelerate their innovation.

Developing a new product is exhilarating. But whether it’s enzyme, oligo, buffer, instrument or application, the path to innovation can be fraught with obstacles. And whether it be customization, R&D, compliance, regulation, kitting or supply chain security the right partner can help to smooth the bumps and straighten the curves.

This webinar examines the challenges assay manufacturers face when searching for a partner for bulk biotech supply. We’ll review key factors for success – development capabilities, customization, confidentiality, quality, scaling and consistency, as well as give an overview of our expansive enzyme portfolio. In this webinar, learn how you can ensure your criteria for formulation, quantities, compliance and timelines are met – an entire strategic plan from discovery to delivery.

The QIAGEN Strategic Partnerships program brings over 40 years of scientific, operational, customization and OEM expertise to the table, allowing businesses of any size to accelerate their innovation.

Developing a new product is exhilarating. But whether it’s enzyme, oligo, buffer, instrument or application, the path to innovation can be fraught with obstacles. And whether it be customization, R&D, compliance, regulation, kitting or supply chain security the right partner can help to smooth the bumps and straighten the curves.

This webinar examines the challenges assay manufacturers face when searching for a partner for bulk biotech supply. We’ll review key factors for success – development capabilities, customization, confidentiality, quality, scaling and consistency, as well as give an overview of our expansive enzyme portfolio. In this webinar, learn how you can ensure your criteria for formulation, quantities, compliance and timelines are met – an entire strategic plan from discovery to delivery.

The QIAGEN Strategic Partnerships program brings over 40 years of scientific, operational, customization and OEM expertise to the table, allowing businesses of any size to accelerate their innovation.

Developing a new product is exhilarating. But whether it’s enzyme, oligo, buffer, instrument or application, the path to innovation can be fraught with obstacles. And whether it be customization, R&D, compliance, regulation, kitting or supply chain security the right partner can help to smooth the bumps and straighten the curves.

This webinar examines the challenges assay manufacturers face when searching for a partner for bulk biotech supply. We’ll review key factors for success – development capabilities, customization, confidentiality, quality, scaling and consistency, as well as give an overview of our expansive enzyme portfolio. In this webinar, learn how you can ensure your criteria for formulation, quantities, compliance and timelines are met – an entire strategic plan from discovery to delivery.

The QIAGEN Strategic Partnerships program brings over 40 years of scientific, operational, customization and OEM expertise to the table, allowing businesses of any size to accelerate their innovation.